Contact Us : (818) 366-8112 | (661) 298-1491

Dr. Jacob Offenberger - Curriculum Vitae


Potrait photo of Dr. Jacob Offenberger founder of Allergy and Asthma Relief Experts in Los Angeles County, San Fernando Valley and Santa Clarita

JACOB OFFENBERGER, M.D.,

F.A.A.P., F.A.A.A.A.I., F.A.C.A.A.I.

Diplomate of the American Board of Allergy and Immunology

Curriculum Vitae:

Education and early experience

  • 1969 – 1972 Paratrooper Combat Medic in Israel Army
  • 1972 – 1975 University of Bologna
    Faculta di Medicine
    Bologna, Italy
  • 1975 – 1980 Sackler Medical School Tel-Aviv, Israel
  • Rotating Internship
    Tel-Aviv University Medical School
    Ichilov Hospital
    Tel-Aviv Yaffo, Israel
  • June 1980 Sackler Medical School
    Tel-Aviv, Israel M.D. Degree
  • 1980 Captain, Medical Officer, Israel Army

Post Doctoral Training:

  • 1/30/1979 – 6/30/1979

    Mobile Coronary Care Unit

    Tel-Aviv, Israel

  • 7/1/1980 - 6/1982
    PL1 Pediatric Residency – UMDNJ
    New Jersey Medical School – Newark, NJ
  • 7/1/1982 – 6/30/1983
    PL3 Chief Resident Pediatrics
    Newark, Beth Israel Medical Center – Newark, NJ
  • 7/1/1983 – 6/30/1985
    Fellowship – Pediatric  Allergy/Immunology
    University of California, San Francisco, CA 

 

Awards & Honors:

  • International Physicians Award
  • Physician of the Year
    • Allergy & Asthma Foundation of Southern Calif

 

Memberships & Offices in Professional Societies:

 

  • 2001 - Present -- Board Member:
    Los Angeles Society of Allergy, Asthma & Clinical Immunology
  • 2008 - Present -- Past President 2008
    Los Angeles Society of Allergy, Asthma & Clinical Immunology

 

Major Research Interests:

  • Asthma
  • Food Allergy
  • Lectures to Physicians, PAC’s, Nurses and Pharmacists on Asthma and Allergy related issue

Articles:

  • Offenberger J, Lieu Tracey, Oscar Frick, and Amann A. Impaired monocyte to macrophange maturation in patients with lymphadenopathy syndrome.  Journal of Clinical Immunology 1986; 6(6), 467-471.

 

  • Cole W., Offenberger J., Frick O, Golden G.A. Chronic Cough in a 59-year-old man.  Ann Allergy 1985; 54(1), 12-13.

 

  • Kirch C. M., Payan D.G., Wong, W.Y.S, Dolman J.G., Blak, V.A., Petri, M.S., Offenberger, J., Goetzl, E.J., Gold, W. The effect of Eicosapentaenoic Acid in Asthma.  Clinical Allergy March 1986; 18(2).

 

Research Projects

2016 HAE study with Shire, 2016

A phase III, randomized, double-blind, placebo-controlled, two-period, three-sequence, partial crossover study to evaluate the efficacy and safety of subcutaneous administration of 2000IU of C1 Esterase Inhibitor (human) liquid for injection for the prevention of angioedema attacks in adolescents and adults with hereditary angioedema.

 

2015 Atopic dermatitis study with Genentech, Inc.

An open-label phase II study to evaluate the safety of Lebrikizumab compared to topical corticosteroids in adult patients with persistent, moderate to severe atopic dermatitis.

 

2015 Chronic Idiopathic Urticaria study with Genentech, Inc.

XTEND-CIU (Xolair treatment efficacy of onger duration in chronic idiopathic Urticaria): A phase IV, multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Omalizumab through 48 weeks in patients with chronic idiopathic Urticaria. Principal Investigator.

 

2014 HAE study with BioCryst Pharmaceuticals

A multicenter, randomized, double-blind, placebo-controlled, 2-period crossover study to evaluate the efficacy and safety of BCX4161 for 12 weeks as an oral prophylaxis treatment for attacks of hereditary angioedema. Principal Investigator.

 

2013 Adult infusion study with Octapharma USA, Inc.

Postmarketing requirement non-interventional 2-armed study to evaluate the safety of Octagam immune globulin intravenous (human) 5% liquid preparation, with a special emphasis on monitoring, analysis and reporting of thromboembolic events (TEFs). Principal Investigator.

 

2013 Adult asthma study with Genentech, Inc.

A prospective observational study to evaluate predictors of clinical effectiveness in response to Omalizumab, Principal Investigator.

 

2012 Asthma study with KaloBios Pharmaceuticals, Inc.

A Phase II, double-blind, placebo-controlled, randomized study to evaluate the  safety, tolerability, and efficacy of KB003 in subjects with asthma inadequately controlled by corticoste.

 

2012 Adult asthma study with TEVA Branded Pharmaceutical Products R&D, I

A 12-week dose-ranging study to evaluate the efficacy and safety of Fp Spiromax (fluticasone propionate inhalation powder) administered twice  daily compared with placebo in adolescent and adult subjects with persistent asthma uncontrolled on non-steroidal therapy.

 

2012 Pediatric asthma study with GlaxoSmithKline

Phase IV, a 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old  with persistent asthma.

 

2012 Adult asthma study with GlaxoSmithKline

Phase IV, a safety and efficacy study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate treatment of  adolescent and adult subjects with asthma.

 

2011 Pediatric asthma study with AstraZeneca

Phase II, double-blind, randomized, parallel-group, placebo-controlled, multi-center study, comparing budesonide pMDI 160ug bid with  placebo, a 6-week efficacy and safety study in children aged 6 to < 12 years with asthma.

 

2011 Chronic Idiopathic Urticaria study with Genentech, Inc.

Phase III randomized double-blind safety study of Xolair in patients with chronic idiopathic Urticaria (CIU) who remain symptomatic despite treatment with H1 antihistamines, H2 blockers, and/or leukotriene receptor antagonists.

 

2010 DX-88/24 HAE study with Dyax Corp.

Phase IV long-term observational safety study to evaluate immunogenicity and hypersensitivity with exposure to Kalbitor (Ecallantide) for the treatment of acute attacks of HAE.

 

2010 C1-Esterase Inhibitor HAE study with CSL Behring.

Non-interventional post-marketing patient registry to evaluate the safety of intravenous administration of Berinert in patients requiring treatment with C1-INH in the US.

 

2010 Pediatric asthma study with GlaxoSmithKline (GSK).

Phase IV randomized double-blind study of FSC 100/50 and FP 100, both twice daily, in a pediatric population during the Fall viral season.

 

2010 XPORT allergic asthma with Genentech, Inc.

Phase IV randomized double-blind study evaluating the persistency of response with or without Xolair after a 5 year therapy.

 

2009 C1-INH HAE study with Jerini and Shire HG Therapies, Inc.

Phase III randomized double-blind study of Icatibant for subcutaneous injection in patients with acute attacks of HAE.

 

2008 DX-88/19 HAE study with Dyax Corp.

Open-label patient continuation of DX-88 (Ecallantide) for acute hereditary angioedema attacks.

 

2007 Excel IgE Sub-Study with Genetech and Novartis

Assessment of Serum IgE levels over time in non-Xolair and Xolair treated patients following discontinuation of Xolair therapy. 3-year study duration.

 

2006 RhC1-INH HAE study with Pharming

Hereditary Angioedema study.

 

2006 EXTRA Study with Genentech
  • Subjects with moderate to severe persistent asthma who are inadequately controlled with LABA and ICS
  • 52 weeks, randomized, double blinded, placebo controlled study

 

2004 Excel Study with Genetech and Novartis
  • Evaluation of Xolair’s Clinical Effectiveness and Long-Term Safety
  • 5 year study